New York, USA – January 19, 2021 – ADC study is always under rapid development, which can be seen from the increasing number of research papers published since 1970. In addition, the cooperations established by the pharmaceutical giants in 2020 indicate that ADC is ushering in a new era with infinite possibilities. Creative Biolabs noticed the great potential of ADC many years ago and kept exploring this field to help researchers working on related projects. To date, Creative Biolabs has gathered a group of scientists who are specialized in conjugation chemistry and really skillful at ADC development.
An ADC molecule is composed of a monoclonal antibody, a cytotoxic payload, and a molecule linker that covalently connects the other two components. Creative Biolabs offers one-stop ADC development service that covers the entire process of the production of the requested ADC molecules. The validated components of ADC after screening are chemically assembled and the resulting ADC molecule will go through in vitro and in vivo analysis to evaluate the biochemical characteristics, such as purity, stability, and drug-to-antibody ration (DAR).
The featured DrugLnk platform enables the development of linker products with desired properties.
Cleavable linker: relies on the inherent properties of a cell cytoplasmic compartments for selective release of the cytotoxic drug.
* pH-sensitive (acid-labile) linkers
* Disulfide linkers
* Protease-sensitive (peptide) linkers
* ß-glucuronide linkers
Non-cleavable linker: has superior stability in the bloodstream with no obvious drug release mechanism.
The scientists with profound knowledge and rich experience are quite skillful at performing lysine conjugation and cysteine conjugation to produce ADCs using the endogenous amino acids as conjugation sites. So as to achieve a narrower DAR, a variety of strategies are adopted during the stage of antibody design to introduce specific and versatile conjugation sites into antibody sequence, including EnCys-mAb, UAAS, and Enzyme-mediated modification and conjugation system.
In addition to the above-mentioned custom services, based upon the exclusive platforms, Creative Biolabs has developed high-quality products required for ADC development, such as linker products, anti-drug antibodies, and anti-antibody ADCs, which are ready for quick global delivery. More details regarding the products and services are available at the official website: https://www.creative-biolabs.com/adc.
Creative Biolabs is a pioneer in the field of biotechnology, which keeps pace with the most recent technology breakthroughs in related fields and provides first-level services. Since its establishment, the company has successfully completed hundreds of projects from global customers. Its competence is well recognized in the industry.